Tharimmune Bilan de santé

Santé financière contrôle des critères 4/6

Tharimmune possède un total de capitaux propres de $3.0M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $5.3M et de $2.2M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$4.77m
Fonds propres	US$3.02m
Total du passif	US$2.23m
Total des actifs	US$5.25m

Mises à jour récentes de la santé financière

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14

Recent updates

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de THAR ( $5.3M ) dépassent ses passifs à court terme ( $2.2M ).

Passif à long terme: THAR n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: THAR est sans dette.

Réduire la dette: THAR n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: THAR dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: THAR dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 43.5 % chaque année

Tharimmune Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Tharimmune Announces 1-for-15 Reverse Stock Split, Intends to Bring it into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Tharimmune Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Hillstream Biopharma Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Hillstream BioPharma, Inc. announced delayed 10-Q filing

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Recent updates

Tharimmune, Inc. Presents Positive Clinical Data at AASLD Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune, Inc. (NasdaqCM:THAR) entered into a nonbinding, exclusive letter of intent to acquire Intract Pharma Ltd.

New major risk - Financial position

Tharimmune, Inc. Appoints David Jones to Its Scientific Advisory Board

Tharimmune, Inc. announced that it has received $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group

Tharimmune, Inc. Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, Its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces 1-for-15 Reverse Stock Split, Intends to Bring it into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Tharimmune, Inc., Annual General Meeting, May 14, 2024

Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104

Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (Pbc)

Tharimmune, Inc. has completed a Follow-on Equity Offering.

Tharimmune Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tharimmune, Inc. has filed a Follow-on Equity Offering.

Hillstream Biopharma Progressing Towards Acquiring Clinical Stage Asset

New major risk - Shareholder dilution

Less than half of directors are independent

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2 HER3 Solid Tumors Via Bispecific and ADC Antibodies and Biologics

Hillstream Biopharma Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Hillstream BioPharma, Inc. announced delayed 10-Q filing

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Hillstream BioPharma, Inc. Announces Initial Results Evaluating the Synergy

Hillstream BioPharma, Inc. Announces Acceptance of Abstract At AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-Functional Inhibitor for Solid Tumors & Leukemias

Hillstream BioPharma, Inc. to Host Virtual R&D Day to Showcase Its Emerging Immuno-Oncology Pipeline Targeting Drug-Resistant Cancers

Hillstream BioPharma Receives Non-Compliance Written Notice from the Nasdaq

Hillstream BioPharma, Inc., Annual General Meeting, Aug 08, 2022

Hillstream BioPharma, Inc. (NasdaqCM:HILS) announces an Equity Buyback for $1 million worth of its shares.

Hillstream BioPharma, Inc. announced delayed annual 10-K filing

Hillstream BioPharma, Inc. has completed an IPO in the amount of $15 million.

No independent directors

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines